Influence of exogenous growth hormone administration on circulating concentrations of α-klotho in healthy and chronic kidney disease subjects: A prospective, single-center open case-control pilot study 11 Medical and Health Sciences 1103 Clinical Sciences

Autor: Adema, Aaltje Y., de Roij van Zuijdewijn, Camiel L. M., Hoenderop, Joost G., de Borst, Martin H., ter Wee, Piet M., Heijboer, Annemieke C., Vervloet, Marc G., Bindels, R., Hoenderop, J. G., de Borst, M. H., Hillebrands, J. L., Navis, G. J., ter Wee, P. M., Vervloet, M. G.
Přispěvatelé: Laboratory for Endocrinology, Amsterdam Gastroenterology Endocrinology Metabolism, AMS - Musculoskeletal Health, Nephrology, AII - Inflammatory diseases, ACS - Diabetes & metabolism, VU University medical center, Clinical chemistry, AGEM - Endocrinology, metabolism and nutrition, Amsterdam Movement Sciences - Rehabilitation & Development, NCA - Brain mechanisms in health and disease
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Zdroj: BMC nephrology, 19(1):327. BioMed Central
BMC Nephrology, 19(1):327. BioMed Central
Adema, A Y, de Roij van Zuijdewijn, C L M, Hoenderop, J G, de Borst, M H, ter Wee, P M, Heijboer, A C, Vervloet, M G, Bindels, R, Hoenderop, J G, de Borst, M H, Hillebrands, J L, Navis, G J, ter Wee, P M & Vervloet, M G 2018, ' Influence of exogenous growth hormone administration on circulating concentrations of α-klotho in healthy and chronic kidney disease subjects: A prospective, single-center open case-control pilot study 11 Medical and Health Sciences 1103 Clinical Sciences ', BMC Nephrology, vol. 19, no. 1, 327 . https://doi.org/10.1186/s12882-018-1114-z
ISSN: 1471-2369
DOI: 10.1186/s12882-018-1114-z
Popis: Background: The CKD-associated decline in soluble α-Klotho (α-Klotho) levels is considered detrimental. Some studies suggest a direct induction of α-Klotho concentrations by growth hormone (GH). In the present study, the effect of exogenous GH administration on α-Klotho concentrations in a clinical cohort with mild chronic kidney disease (CKD) and healthy subjects was studied. Methods: A prospective, single-center open case-control pilot study was performed involving 8 patients with mild CKD and 8 healthy controls matched for age and sex. All participants received subcutaneous GH injections (Genotropin®, 20 mcg/kg/day) for 7 consecutive days. α-Klotho concentrations were measured at baseline, after 7 days of therapy and 1 week after the intervention was stopped. Results: α-Klotho concentrations were not different between CKD-patients and healthy controls at baseline (554 (388-659) vs. 547 (421-711) pg/mL, P = 0.38). Overall, GH therapy increased α-Klotho concentrations from 554 (405-659) to 645 (516-754) pg/mL, P < 0.05). This was accompanied by an increase of IGF-1 concentrations from 26.8 ± 5.0 nmol/L to 61.7 ± 17.7 nmol/L (P < 0.05). GH therapy induced a trend toward increased α-Klotho concentrations both in the CKD group (554 (388-659) to 591 (358-742) pg/mL (P = 0.19)) and the healthy controls (547 (421-711) pg/mL to 654 (538-754) pg/mL (P = 0.13)). The change in α-Klotho concentration was not different for both groups (P for interaction = 0.71). α-Klotho concentrations returned to baseline levels within one week after the treatment (P < 0.05). Conclusions: GH therapy increases α-Klotho concentrations in subjects with normal renal function or stage 3 CKD. A larger follow-up study is needed to determine whether the effect size is different between both groups or in patients with more severe CKD. Trial registration: This trial is registered in EudraCT (2013-003354-24).
Databáze: OpenAIRE
Externí odkaz: